This is clinically relevant since a therapy that inhibits pancreatic lipases has entered clinical trials with a goal to prevent organ failure (ClinicalTrials.gov ID NCT06080789) and could be tested in clinical trials of heart failure. Here, PNLIP is linked to heart failure.